Aestis

Aestis Therapeutics was a biotechnology company focused on the discovery and development of small molecule therapeutics for obesity and metabolic disorders. The company's primary technological focus was on peripherally restricted cannabinoid-1 (CB1) receptor antagonists. This approach aimed to harness the weight-loss and metabolic improvements associated with CB1 inhibition while minimizing the psychiatric side effects typically caused by drugs that cross the blood-brain barrier. Based in Farmington, Connecticut, Aestis was supported by venture capital from firms such as Connecticut Innovations and Elm Street Ventures. The company was a participant in the University of Connecticut's technology incubator program. Aestis is currently inactive and has ceased its development programs.